早期原发性肝细胞癌患者治疗方式的个体化选择研究进展  

Research progress of individualized choice of treatment for early-stage primary hepatocellular carcinoma patients

作　　者：姜雪薇 丹增阿旺 袁宵寅 郭玲 何正为 杨振华 伍行 张斌豪 Jiang Xuewei;Danzeng Awang;Yuan Xiaoyin;Guo Ling;He Zhengwei;Yang Zhenhua;Wu Hang;Zhang Binhao(Department of Hepato-pancreato-biliary Surgery,Tianyou Hospital,Wuhan University of Science and Technology,Wuhan 430064,China;Hepatic Surgery Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]武汉科技大学附属天佑医院肝胆胰外科,武汉430064 [2]华中科技大学同济医学院附属同济医院肝脏外科中心,武汉430030

出　　处：《中华肝胆外科杂志》2025年第3期231-236,共6页Chinese Journal of Hepatobiliary Surgery

基　　金：湖北陈孝平科技发展基金会(CXPJJH121001-2021004、CXPJJH122005-20);知识创新专项-武汉曙光计划项目(2023020201020406)。

摘　　要：肝细胞癌是常见的恶性肿瘤,严重影响公共卫生健康,随着医学的发展和体检意识的提高,早期肝细胞癌的诊断率逐渐提高,越来越多的患者在初诊时可接受根治性治疗,另外,治疗方式的持续发展使患者和临床医生有更多的选择,如何进行合理选择实现个体化精准医疗值得深入探讨。本文总结了早期肝细胞癌患者治疗方式个体化选择的研究进展,为临床工作者提供参考。Hepatocellular carcinoma(HCC)is a prevalent malignant tumor that poses a significant threat to public health.Advances in medical science and increased screening awareness have improved early-stage diagnosis rates,allowing more patients to undergo radical treatment at initial diagnosis.Concurrently,ongoing developments in treatment modalities have expanded the options available for both patients and clinicians.The challenge now lies in making informed decisions to achieve individualized precision medicine,which merits thorough exploration.This article aims to review the latest research on personalized treatment strategies for early-stage HCC,providing a reasonable reference and valuable insights for clinicians.

关 键 词：癌 肝细胞 肝移植 肝切除术 射频消融 放射治疗 个体化 

分 类 号：R735.7[医药卫生—肿瘤]